CD24 expression predicts distant metastasis in extrahepatic bile duct cancer

Table 2 Univariate analysis for loco-regional relapse-free, distant metastasis-free and overall survival

Variables	n	5-yr LRRFS	P value	5-yr DMFS	P value	5-yr OS	P value
Age
≤ 60 yr	37	62.1%	0.3615	53.6%	0.6837	35.1%	0.3495
> 60 yr	47	63.0%		37.9%		51.4%
Residual disease
R0	62	76.3%	0.0356	49.6%	0.7748	53.1%	0.2421
R1	22	33.4%		25.6%		27.3%
Tumor location1
Proximal	59	54.1%	0.1236	34.8%	0.0623	38.7%	0.0288
Distal	22	79.9%		67.0%		59.7%
T stage
T1-2	33	59.2%	0.6311	48.3%	0.4501	49.4%	0.9502
T3-4	51	64.3%		40.4%		42.2%
N stage2
N0	48	67.5%	0.7606	64.2%	0.0003	51.7%	0.0514
N1	33	54.4%		15.8%		30.8%
Histologic differentiation3
W/D	15	69.8%	0.2003	66.0%	0.0394	35.0%	0.3538
M/D	59	60.7%		41.4%		50.2%
P/D	8	36.5%		0%		25.0%
Use of maintenance chemotherapy
No	16	59.5%	0.5444	35.2%	0.1976	33.7%	0.1435
Yes	68	62.7%		45.2%		47.3%
CD24 expression
Negative	48	68.9%	0.3519	55.1%	0.0100	50.3%	0.1873
Positive	36	49.9%		29.0%		37.2%

¹3 patients with tumor extending from the proximal to distal bile duct were excluded;

²In 3 patients, lymph node dissection was not performed;

³In 2 patients, the information on histologic differentiation was unavailable. LRRFS: Loco-regional relapse-free survival; DMFS: Distant metastasis-free survival; OS: Overall survival; R0: No microscopic residual disease; R1: Microscopic residual disease; W/D: Well differentiated; M/D: Moderately differentiated; P/D: Poorly differentiated.